Citigroup Inc Lian Bio Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$1.49 - $2.46 $136,180 - $224,834	-91,396 Reduced 12.92%	615,940 $917,000
Q2 2023 Aug 10, 2023	SELL	$1.79 - $2.85 $29,177 - $46,455	-16,300 Reduced 2.25%	707,336 $1.61 Million
Q1 2023 May 11, 2023	BUY	$1.57 - $2.66 $25,591 - $43,358	16,300 Added 2.3%	723,636 $1.42 Million
Q3 2022 Nov 10, 2022	BUY	$1.87 - $3.0 $483,987 - $776,451	258,817 Added 57.7%	707,336 $1.41 Million
Q2 2022 Aug 10, 2022	SELL	$2.15 - $6.01 $183,343 - $512,508	-85,276 Reduced 15.98%	448,519 $969,000

Q1 2022 May 12, 2022	BUY	$2.8 - $6.21 $1.49 Million - $3.31 Million	533,795 New	533,795 $1.98 Million

1.09M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $32.5M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.